修订版2022欧洲白血病网危险分层在成人急性髓系白血病患者中的验证
该研究纳入1570例新诊断急性髓系白血病(AML)患者(中位年龄56岁),接受以阿糖胞苷为基础的强化化疗,验证2022欧洲白血病网(ELN)危险分层的预后价值。与2017 ELN分层相比,2022 ELN分层使340例(22%)患者危险分组被修订,总生存的3年曲线下面积从0.67提升至0.71。作者建议重新评估伴骨髓增生异常相关基因突变患者的危险分层。
要点
- 2022 ELN分层较2017版改善总生存的预后区分度(3年AUC 0.71 vs 0.67)。
- 340例(22%)患者危险分组被修订,多重新归入2022 ELN中危或高危组。
- 2022 ELN低危组中伴骨髓增生异常相关基因突变未显著影响结局。
核心结论
- 2022 ELN分类在大型强化治疗AML队列中改善预后区分度。
- 鉴于骨髓增生异常相关基因突变患者结局异质,介于中危和高危之间,作者建议重新评估这些患者的危险分层。
研究设计与样本
- 研究纳入1570例新诊断AML患者,中位年龄56岁,接受以阿糖胞苷为基础的强化化疗方案。
- 研究比较2022 ELN分类(ELN22)与2017 ELN分类(ELN17)的预后价值。
主要发现
- ELN17将595例(38%)、413例(26%)、562例(36%)分别归为低危、中危、高危;ELN22将575例(37%)、410例(26%)、585例(37%)分别归为低危、中危、高危。
- 340例(22%)患者危险分组被修订,多数重新归入ELN22中危或高危组。
- 按ELN22危险分组,无事件生存、无复发生存和总生存均显著不同。
- 与ELN17相比,按ELN22重新分配对总生存的预后区分度显著改善(3年曲线下面积0.71 vs 0.67)。
- 在ELN22低危组中,伴骨髓增生异常相关基因突变未显著影响结局;在ELN22高危组中,骨髓增生异常相关基因突变患者5年总生存率为21%,TP53突变患者为3%。
关键数值与推荐
- 在携带骨髓增生异常相关基因突变的患者中,EZH2、STAG2和ZRSR2突变患者的总生存呈中危样。
- 在继发性AML患者和接受异基因造血细胞移植的患者中,ELN22各危险组间无事件生存和总生存显著不同,而ELN17与ELN22的预后能力相似。
临床怎么用
- 作者建议重新评估骨髓增生异常相关基因突变患者的危险分层。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
In 2022, the European LeukemiaNet (ELN) risk stratification for patients with acute myeloid leukemia (AML) has been updated. We aimed to validate the prognostic value of the 2022 ELN classification (ELN22) by evaluating 1570 patients with newly diagnosed AML (median age, 56 years) treated with cytarabine-based intensive chemotherapy regimens. Compared with 2017 ELN classification (ELN17), which allocated 595 (38%), 413 (26%), and 562 patients (36%) to the favorable-, intermediate-, and adverse-risk categories, ELN22 classified 575 (37%), 410 (26%), and 585 patients (37%) as favorable, intermediate, and adverse risk, respectively. Risk group allocation was revised in 340 patients (22%). Most patients were reclassified into the ELN22 intermediate- or ELN22 adverse-risk group. The allocation of patients according to the ELN22 risk categories resulted in a significantly distinct event-free survival (EFS), relapse-free survival, and overall survival (OS). Compared with ELN17, reallocation according to the ELN22 recommendations resulted in a significantly improved prognostic discrimination for OS (3-year area under the curve, 0.71 vs 0.67). In patients with ELN22 favorable-risk AML, co-occurring myelodysplasia-related (MR) gene mutations did not significantly affect outcomes. Within the ELN22 adverse-risk group, we observed marked survival differences across mutational groups (5-year OS rate of 21% and 3% in patients with MR gene mutations and TP53 mutations, respectively). In patients harboring MR gene mutations, EZH2-, STAG2-, and ZRSR2-mutated patients showed an intermediate-like OS. In patients with secondary AML and those who underwent allogeneic hematopoietic cell transplantation, EFS and OS significantly differed between ELN22 risk groups, whereas the prognostic abilities of ELN17 and ELN22 classifications were similar. In conclusion, ELN22 improves prognostic discrimination in a large cohort of intensively treated patients with AML. Given the heterogeneous outcome in patients with MR gene alterations, ranging between those of intermediate and adverse risk patients, we suggest re-evaluation of risk allocation in these patients.
引用
- Ruhnke L, Bill M, Zukunft S, et al. Validation of the revised 2022 European LeukemiaNet risk stratification in adult patients with acute myeloid leukemia. Blood Adv. 2025. PMID: 39504561. doi:10.1182/bloodadvances.2024013304
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。